- Home
- SNSE vs PHGE Comparison
SNSE vs PHGE Comparison
Compare SNSE & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- PHGE
- Stock Information
- Founded
- SNSE 2005
- PHGE 2015
- Country
- SNSE United States
- PHGE Israel
- Employees
- SNSE N/A
- PHGE N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- PHGE Health Care
- Exchange
- SNSE Nasdaq
- PHGE Nasdaq
- Market Cap
- SNSE 11.2M
- PHGE 12.6M
- IPO Year
- SNSE 2021
- PHGE N/A
- Fundamental
- Price
- SNSE $11.13
- PHGE $0.57
- Analyst Decision
- SNSE Strong Buy
- PHGE Strong Buy
- Analyst Count
- SNSE 4
- PHGE 1
- Target Price
- SNSE $72.50
- PHGE $15.00
- AVG Volume (30 Days)
- SNSE 3.5K
- PHGE 292.1K
- Earning Date
- SNSE 11-13-2025
- PHGE 11-13-2025
- Dividend Yield
- SNSE N/A
- PHGE N/A
- EPS Growth
- SNSE N/A
- PHGE N/A
- EPS
- SNSE N/A
- PHGE N/A
- Revenue
- SNSE N/A
- PHGE N/A
- Revenue This Year
- SNSE N/A
- PHGE N/A
- Revenue Next Year
- SNSE N/A
- PHGE N/A
- P/E Ratio
- SNSE N/A
- PHGE N/A
- Revenue Growth
- SNSE N/A
- PHGE N/A
- 52 Week Low
- SNSE $5.00
- PHGE $0.34
- 52 Week High
- SNSE $17.40
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- SNSE 71.14
- PHGE 59.74
- Support Level
- SNSE $9.35
- PHGE $0.50
- Resistance Level
- SNSE $10.00
- PHGE $0.54
- Average True Range (ATR)
- SNSE 0.51
- PHGE 0.03
- MACD
- SNSE 0.09
- PHGE 0.00
- Stochastic Oscillator
- SNSE 94.27
- PHGE 86.32
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).